---
title: "Healthcare Industry Daily (04.19): Frontline Dynamics in Pharmaceuticals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283262830.md"
description: "KHPG's subsidiary KHN921 injection has received FDA clinical trial approval for the indication of hypertrophic cardiomyopathy. A team from Nanjing Medical University has developed a new nanoenzyme that effectively treats diabetes-induced erectile dysfunction. Research from Jinan University has found that targeting PKM2 can promote mucosal repair and slow the progression of colitis. Kanion Pharmaceutical has received the clinical trial approval notice for Qingcentongluo granules"
datetime: "2026-04-19T19:11:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283262830.md)
  - [en](https://longbridge.com/en/news/283262830.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283262830.md)
---

# Healthcare Industry Daily (04.19): Frontline Dynamics in Pharmaceuticals

## Company News

> **KHPG: Subsidiary KHN921 Injection Receives Clinical Trial Approval from the US FDA**
> 
> According to a report from Caixin, on April 19, KHPG (002773.SZ) announced that its subsidiary Chengdu Hongji Biotechnology Co., Ltd. recently received an email from the US Food and Drug Administration (FDA) granting permission for its self-developed KHN921 injection to conduct clinical trials in the United States. This drug is an AAV gene therapy product indicated for hypertrophic cardiomyopathy (HCM) associated with MYBPC3 gene mutations.

> **Adv Sci | Nanjing Medical University Team Develops New Nanoenzyme to Reverse Diabetes-Induced Penile Cavernositis and Epigenetic Abnormalities, Effectively Treating Erectile Dysfunction**
> 
> A team from Nanjing Medical University published research in Advanced Science, establishing a framework combining single-cell RNA sequencing and machine learning to design nanoenzymes for the treatment of diabetes-induced erectile dysfunction (DMED). The study found that reactive oxygen species levels were elevated in the penile cavernous tissue of DMED patients, with downregulated expression of antioxidant enzymes. The iron-based single-atom nanoenzyme Fe-DMOF exhibited GPx-like, CAT-like, and SOD-like triple activities, reducing ROS accumulation and inhibiting inflammatory differentiation, validating the effectiveness of the "scRNA-seq+ML" framework in disease-specific nanoenzyme design.

> **GUT: Metabolic Reprogramming "Turning Over a New Leaf": Jinan University Research Team Discovers Targeting Macrophage PKM2 Promotes Mucosal Repair and Inhibits Colitis Progression**
> 
> Research from Jinan University and other institutions found that targeting PKM2-dependent glycolysis reprograms monocytes into Cadm1+ macrophages, promoting mucosal repair and slowing the progression of ulcerative colitis (UC). This study revealed that the upregulation of macrophage PKM2 in inflamed intestinal tissue is associated with disease severity and colitis progression, providing potential targets for UC treatment.

> **KHPG: Receives Clinical Trial Approval Notification for Qing Shen Tong Luo Granules**
> 
> On April 19, KHPG announced that it recently received the "Drug Clinical Trial Approval Notification" for Qing Shen Tong Luo Granules issued by the National Medical Products Administration. According to the Drug Administration Law of the People's Republic of China and relevant regulations, the clinical trial application for Qing Shen Tong Luo Granules accepted on January 28, 2026, meets the relevant requirements for drug registration. Based on further improvement of the clinical trial protocol, approval has been granted for this product to conduct confirmatory clinical trials (Phase III) for the syndrome of damp-heat obstruction in rheumatoid arthritis.

> **China Biologic Products (01177): Lixin Pharmaceutical to Present Preliminary Clinical Data for MK-2010/LM-299 at AACR 2026**
> 
> According to Zhitong Finance APP, China Biologic Products (01177) announced that its wholly-owned subsidiary Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. ("Lixin Pharmaceutical") will present preliminary clinical data for its innovative drug MK-2010/LM-299 "PD-1/VEGF Dual Antibody" at the 2026 American Association for Cancer Research (AACR) Annual Meeting In November 2024, Lixin Pharmaceutical reached a global exclusive licensing agreement with Merck & Co., Inc. (known as MSD outside the United States and Canada) in Rahway, New Jersey, granting MSD exclusive rights to develop, manufacture, and commercialize LM-299 worldwide. MK-2010/LM-299 is an investigational tetravalent bispecific antibody that simultaneously targets programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF), utilizing an IgG-VHH fusion structure with Fcγ silencing functionality. The treatment strategy based on PD-1 inhibition combined with VEGF blockade has shown clinical efficacy in various advanced solid tumors, whether through combination therapy or bispecific antibodies.

## Industry Dynamics

> **Healthcare Industry Daily (04.18): Pharmaceutical Frontline Dynamics**
> 
> A team from Shanghai Jiao Tong University reveals the mechanism of RIPK3 in regulating cell death; Abbott releases its Q1 2026 financial report, showing global sales growth; First Pharmaceutical reports revenue growth in 2025 but a decline in net profit; Academician Ying Hanjie joins Fudan University School of Pharmacy; A team from Tsinghua University develops a generative AI model for single-cell multi-omics data; Three gene therapies from China are racing for FDA approval; Electromagnetic field technology can be used to reverse aging and treat diseases; A health science report for medical staff is released; Implementation rules for the supervision and management of medical insurance fund usage are enacted.

> **Could what you think is "chronic gastrointestinal disease" actually be a "disguised latent" condition?**
> 
> News Summary: This popular science article reveals that early symptoms of gastrointestinal tumors are often overlooked, emphasizing the importance of gastrointestinal endoscopy screening. The article points out that early gastric cancer and colorectal cancer may not have obvious symptoms and can be easily misdiagnosed. Experts recommend that individuals over 45 should undergo regular gastrointestinal endoscopy screening, with high-risk groups advised to start earlier. The article also discusses the types of gastrointestinal tumors, high-risk populations, preventive measures, and related issues regarding gastrointestinal endoscopy, such as painless endoscopy and the use of laxatives. It emphasizes that maintaining a healthy lifestyle, such as a balanced diet and moderate exercise, can reduce the risk of gastrointestinal tumors.

> **3SBio's Bispecific Antibody Matrix is Exploding**
> 
> 3SBio is building a complete bispecific antibody system, with 19 investigational bispecific antibody drugs currently in development, 9 of which have entered clinical stages. The products cover multiple fields, including oncology, autoimmunity, and metabolism, with PD1/VEGF as the core, aiming to expand growth space.

> **Commercial Insurance Payment for Innovative Drugs: Doing the Difficult but Right Thing**
> 
> The General Office of the State Council issued "Several Opinions on Improving the Drug Price Formation Mechanism," emphasizing the acceleration of the role of commercial health insurance and broadening payment channels for innovative drugs. In 2025, the "Commercial Health Insurance Innovative Drug Catalog" will include 19 innovative drugs not covered by medical insurance for the first time. The payment for innovative drugs faces implementation challenges, requiring commercial insurance to deeply integrate with healthcare, medical insurance, and pharmaceuticals. It is necessary to optimize the performance assessment system of medical institutions, address risk control issues for insurance companies, break down data barriers, achieve data interoperability and sharing for diagnosis, treatment, medication, claims, and settlement, and build a multi-level medical security system **Daily Yi News | JAMA Subjournal: Tirzepatide Significantly Improves Prognosis in Diabetic Patients with Comorbid Cardiovascular Disease**
> 
> Tirzepatide outperforms dulaglutide in reducing the risk of cardiorenal complications and mortality in patients with type 2 diabetes and comorbid cardiovascular disease. The SURPASS study results show that the risk of primary cardiorenal endpoint events in the tirzepatide group was reduced by 16%, including all-cause mortality, coronary revascularization, and renal composite endpoints. In terms of safety, the incidence of gastrointestinal adverse reactions was slightly higher in the tirzepatide group, but overall tolerability was good. This finding provides important evidence for clinical drug selection, suggesting that tirzepatide may be a superior treatment option.

_This article was generated by Xiao Ou AI based on data from Yiou. If you have any questions or suggestions, please feel free to contact us through the contact information on our website._

### Related Stocks

- [600557.CN](https://longbridge.com/en/quote/600557.CN.md)
- [002773.CN](https://longbridge.com/en/quote/002773.CN.md)
- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [600833.CN](https://longbridge.com/en/quote/600833.CN.md)
- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)
- [688336.CN](https://longbridge.com/en/quote/688336.CN.md)

## Related News & Research

- [DOJ unveils charges for $6.5 billion in health fraud schemes](https://longbridge.com/en/news/290599756.md)
- [09:12 ETK-Laser Launches GIRO, Advancing the Future of Rehabilitation and Sports Medicine](https://longbridge.com/en/news/290838410.md)
- [REG - EDX Medical Group - Results of General Meeting](https://longbridge.com/en/news/290973486.md)
- [ZAWYA: Specialized Rehabilitation Hospital breaks ground on major extension to create the UAE’s largest integrated rehabilitation hospital](https://longbridge.com/en/news/291039123.md)
- [Beijing Biostar Wins Shareholder Backing for Capital Mandates and Governance Changes at AGM](https://longbridge.com/en/news/290979536.md)